Who makes Carbetocin Bolus application?

Carbetocin Bolus application is developed by University Hospital, Basel, Switzerland.

What development phase is Carbetocin Bolus application in?

Carbetocin Bolus application is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Carbetocin Bolus application

University Hospital, Basel, Switzerland · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Carbetocin Bolus application
Sponsor	University Hospital, Basel, Switzerland
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections (PHASE4)
Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Carbetocin Bolus application CI brief — competitive landscape report
Carbetocin Bolus application updates RSS · CI watch RSS
University Hospital, Basel, Switzerland portfolio CI